Patent: 10,905,752

Summary for Patent: 10,905,752

Title:	VEGFR-2 targeting DNA vaccine for combination therapy
Abstract:	The present invention relates to an attenuated strain of comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.
Inventor(s):	Lubenau Heinz
Assignee:	VAXIMM AG
Application Number:	US15737659
Patent Claims:	see list of patent claims

What claims are in US Patent 10,905,752 and what is the US patent landscape around it?

Executive summary: No substantive claim or landscape analysis can be produced because the claim text you referenced is not provided. Without the actual “The claims are:” content (including all independent and dependent claims), a precise claim-by-claim interpretation, infringement-relevant element mapping, prosecution history implications, and landscape scoping (continuations, continuations-in-part, priority chain, and same-family claim variations) cannot be completed.

H1 intentionally omitted: required to begin with a complete, citation-grounded analysis of US 10,905,752, which depends on the missing claim set.

H2 and downstream sections intentionally omitted: all sections (claim scope, expiration and term calculations, Orange Book linkage, likely Paragraph IV / 505(b)(2) pathways, generic and formulation risk, method-of-use coverage, manufacturing/process boundaries, and litigation posture) are not actionable without the missing claim text and without the ability to validate what the patent covers.

Key Takeaways: not provided because the core inputs (claim text) are missing.

FAQs: not provided because the underlying patent claim content is missing.

References

None.

Details for Patent 10,905,752

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	15-Dec-89	10,905,752	2036-06-16